Research Analysts Offer Predictions for SNDX FY2027 Earnings

Key Points

• Analysts at B. Riley have revised Syndax Pharmaceuticals' FY2027 earnings per share forecast downward to $0.05, down from a previous prediction of $0.12, while maintaining a "Strong-Buy" rating.
• The company's recent quarterly earnings report showed earnings of ($0.83) per share, exceeding expectations, with a significant revenue increase of 984.5% year-over-year.
• Insider trading activity included CEO Michael A. Metzger selling 157,307 shares of the stock, representing a 34.50% decrease in his ownership stake.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Investment analysts at B. Riley decreased their FY2027 earnings per share (EPS) estimates for shares of Syndax Pharmaceuticals in a report issued on Friday, October 3rd. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of $0.05 for the year, down from their previous forecast of $0.12. B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.18. The firm had revenue of $37.96 million for the quarter, compared to analysts' expectations of $26.64 million. Syndax Pharmaceuticals had a negative return on equity of 130.47% and a negative net margin of 428.48%.The company's quarterly revenue was up 984.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.80) EPS.

Several other analysts have also issued reports on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Syndax Pharmaceuticals in a report on Saturday, September 27th. Stifel Nicolaus assumed coverage on Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They issued a "buy" rating and a $44.00 price target on the stock. UBS Group decreased their price target on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. BTIG Research reaffirmed a "buy" rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a report on Friday, September 19th. Finally, Guggenheim began coverage on shares of Syndax Pharmaceuticals in a report on Thursday, September 4th. They set a "buy" rating and a $34.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $39.22.

Syndax Pharmaceuticals Stock Up 1.0%

SNDX stock opened at $15.60 on Monday. The company has a debt-to-equity ratio of 2.06, a current ratio of 4.71 and a quick ratio of 4.55. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -4.01 and a beta of 0.68. The business's fifty day moving average price is $14.61 and its two-hundred day moving average price is $12.16. Syndax Pharmaceuticals has a fifty-two week low of $8.58 and a fifty-two week high of $22.50.

Institutional Investors Weigh In On Syndax Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the business. Hudson Bay Capital Management LP increased its holdings in Syndax Pharmaceuticals by 77.3% in the second quarter. Hudson Bay Capital Management LP now owns 443,300 shares of the company's stock worth $4,152,000 after purchasing an additional 193,300 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company's stock worth $79,000 after purchasing an additional 4,308 shares in the last quarter. Soleus Capital Management L.P. increased its holdings in Syndax Pharmaceuticals by 33.7% in the second quarter. Soleus Capital Management L.P. now owns 1,092,110 shares of the company's stock worth $10,228,000 after purchasing an additional 275,500 shares in the last quarter. Man Group plc increased its holdings in Syndax Pharmaceuticals by 70.1% in the second quarter. Man Group plc now owns 228,167 shares of the company's stock worth $2,137,000 after purchasing an additional 94,031 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Syndax Pharmaceuticals in the second quarter worth approximately $66,000.

Insider Buying and Selling

In related news, CEO Michael A. Metzger sold 157,307 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $16.41, for a total value of $2,581,407.87. Following the transaction, the chief executive officer directly owned 298,661 shares of the company's stock, valued at $4,901,027.01. The trade was a 34.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Dennis Podlesak sold 19,200 shares of Syndax Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.84, for a total value of $304,128.00. Following the completion of the transaction, the director directly owned 191,763 shares in the company, valued at approximately $3,037,525.92. This represents a 9.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 204,537 shares of company stock worth $3,265,935. 4.10% of the stock is owned by insiders.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.